Eupraxia Pharmaceuticals Inc. EPRX

EPRX Company Overview

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing localized, extended-release therapeutics designed to improve the delivery and durability of anti-inflammatory treatments. The company operates primarily in the biopharmaceutical industry, with a strategic emphasis on conditions where sustained local drug exposure may improve efficacy while reducing systemic side effects. Eupraxia’s core platform is based on its proprietary DiffuSphere™ technology, which is designed to provide controlled release of active pharmaceutical ingredients directly at the target site over extended periods.

The company’s primary development programs have focused on eosinophilic esophagitis (EoE), osteoarthritis, and other inflammatory conditions. Its lead product candidate, EP-104GI, is being evaluated for EoE using localized delivery of fluticasone propionate to the esophagus. Eupraxia has also advanced EP-104IAR for intra-articular inflammatory conditions such as knee osteoarthritis. Founded in Canada and headquartered in Victoria, British Columbia, the company evolved from a drug-delivery technology platform into a clinical-stage therapeutics developer targeting specialty inflammatory diseases with unmet medical need.